merged_340b-apexus-drugs-middleman.txt
<other>First, I will analyze the article to find the relevant information for each question.</other>
<question_number>1</question_number>
<answer>Apexus</answer>
<other>The article mentions that Apexus was initially established as a nonprofit but became a for-profit company in 2014 and capitalized on the 340B program expansion.</other>
<question_number>2</question_number>
<answer>Apexus</answer>
<other>The former congressional committee staff member, Marsha Simon, described Apexus as having "a license to hunt."</other>
<question_number>3</question_number>
<answer>Apexus</answer>
<other>The purchasing optimization team of Apexus analyzes hospital drug-buying patterns, and the company gives bonuses to employees for revenue increases despite government directives to focus solely on program administration.</other>
<question_number>4</question_number>
<answer>Virginia King</answer>
<other>Virginia King's experience highlighted the price disparity when she switched from Christus St. Vincent hospital charging $22,700 to a non-participating clinic charging $8,000 for the same injection.</other>
<question_number>5</question_number>
<answer>340B Drug Pricing Program</answer>
<other>The 340B program's costs increased by more than 200 percent over three years in New York state, leading to Medicaid administration changes in 2023.</other>
<question_number>6</question_number>
<answer>Apexus</answer>
<other>Apexus developed a $750 certification course and provided broad interpretations of patient eligibility rules, allowing hospitals to review records up to 36 months back.</other>
<question_number>7</question_number>
<answer>Apexus acting like a sales-driven business rather than a program administrator</answer>
<other>Krista Pedley criticized Apexus for acting like a sales-driven business rather than a program administrator during a Skype meeting.</other>
<question_number>8</question_number>
<answer>North Carolina</answer>
<answer>The North Carolina state health plan was billed 85% more for certain cancer drugs by participating hospitals compared to non-participating ones, with melanoma treatment showing a markup from $8,000 to $21,512.</answer>
<question_number>9</question_number>
<answer>Acentrus</answer>
<other>Acentrus was the service sold by Apexus that helped hospitals provide data to manufacturers in exchange for deeper discounts on specialty drugs used to treat conditions like cancer and HIV.</other>
<question_number>10</question_number>
<answer>Apexus</answer>
<other>Apexus, based in Texas, charges a 3% fee for generic drug line management and collects fees on non-340B drug purchases. Baxter attempted unsuccessfully to bypass this arrangement in 2021.</other>